SCHEMBL462209

SCHEMBL462209

CCCCCN1CCOC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.47
SIGMAR1 Q99720 2/20 0.47
ALDH1A1 P00352 2/20 0.47
CYP1A2 P05177 1/20 0.47
CHRM2 P08172 1/20 0.47
CHRM1 P11229 1/20 0.47
HTR2A P28223 1/20 0.47
SCN1A P35498 1/20 0.47
HTR2B P41595 1/20 0.47
KCNH2 Q12809 1/20 0.47
SCN2A Q99250 1/20 0.47
SCN3A Q9NY46 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
USP2 O75604 1/20 0.46
LMNA P02545 1/20 0.46
GNAI3 P08754 4/20 0.44
GNAO1 P09471 4/20 0.44
GNAI1 P63096 4/20 0.44
KEAP1 Q14145 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9549214 0.98 GNAI3 (0.47) MAPK1SIGMAR1ALDH1A1CYP1A2CHRM2
SCHEMBL11504373 0.98 GNAI3 (0.47) MAPK1SIGMAR1ALDH1A1CYP1A2CHRM2
SCHEMBL11504584 0.98 GNAI3 (0.47) MAPK1SIGMAR1ALDH1A1CYP1A2CHRM2
SCHEMBL3130672 0.93
SCHEMBL15996236 0.88 GNAI3 (0.41) MAPK1SIGMAR1ALDH1A1CYP1A2CHRM2
SCHEMBL9806563 0.88 MGLL (0.41) MAPK1SIGMAR1ALDH1A1CYP1A2CHRM2
SCHEMBL9806579 0.88 MGLL (0.41) MAPK1SIGMAR1ALDH1A1CYP1A2CHRM2
SCHEMBL40487 0.86 ALDH1A1 (0.59) MAPK1SIGMAR1ALDH1A1CYP1A2CHRM2
SCHEMBL5251269 0.86 ALDH1A1 (0.59) MAPK1SIGMAR1ALDH1A1CYP1A2CHRM2
SCHEMBL11504301 0.86 SMN1; SMN2 (0.50) MAPK1SIGMAR1ALDH1A1CYP1A2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3262089-A1 A PROCESS FOR PRODUCING SURFACE-POSTCROSSLINKED WATER-ABSORBENT POLYMER PARTICLES BY POLYMERIZING DROPLETS OF A MONOMER SOLUTION BASF SE (DE) 2018-01-03 EP claimed
WO-2016134905-A1 A PROCESS FOR PRODUCING SURFACE-POSTCROSSLINKED WATER-ABSORBENT POLYMER PARTICLES BY POLYMERIZING DROPLETS OF A MONOMER SOLUTION BASF SE (DE) 2016-09-01 WO claimed
WO-2008057948-A2 PROCESSES FOR PRODUCTION OF DIPHENYLYLAZETIDIN-2-ONES AND RELATED COMPOUNDS IRONWOOD PHARMACEUTICALS, INC. (US) 2008-05-15 WO claimed
EP-0175250-B1 AGENT AND PROCESS FOR THE DETERMINATION OF REDOX SYSTEMS Roche Diagnostics GmbH (DE) 1990-05-09 EP claimed
EP-0175250-A2 Agent and process for the determination of redox systems Roche Diagnostics GmbH (DE) 1986-03-26 EP claimed
EP-1791894-B1 PARTICULATE WATER-ABSORBING AGENT CONTAINING WATER-ABSORBENT RESIN AS A MAIN COMPONENT NIPPON CATALYTIC CHEM IND (JP) 2020-10-21 EP disclosed
US-9750651-B2 Absorbent article with profiled acquisition-distribution system THE PROCTER & GAMBLE COMPANY (US) 2017-09-05 US disclosed
EP-1888727-B1 NEW DHA DERIVATIVES AND THEIR USE AS MEDICAMENTS PRONOVA BIOPHARMA NORGE AS (NO) 2015-04-15 EP disclosed
US-20140163504-A1 ABSORBENT ARTICLE WITH PROFILED ACQUISITION-DISTRIBUTION SYSTEM THE PROCTER & GAMBLE COMPANY (US) 2014-06-12 US disclosed
US-8618165-B2 Compounds PRONOVA BIOPHARMA NORGE AS (NO) 2013-12-31 US disclosed
US-20130210704-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF S&T GLOBAL INC. (US) 2013-08-15 US disclosed
EP-2258870-B1 Method for identifying compounds which bind to biological target molecule GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
EP-0332387-A1 Triazole derivatives, their preparation and their use as fungicides Sankyo Company Limited (JP) 1989-09-13 EP disclosed
US-4820632-A ANILINE DERIVATIVE AND OXIDIZABLE COUPLER COLORED COMPOUND FOR DETECTION OF HYDROGEN PEROXIDE; MEDICAL DIAGNOSIS BOEHRINGER MANNHEIM GMBH (DE) 1989-04-11 US disclosed
EP-0175250-A2 Agent and process for the determination of redox systems Roche Diagnostics GmbH (DE) 1986-03-26 EP disclosed
EP-0063299-A1 Process for the preparation of N-aryl-2,4-oxazolidine diones BAYER AG (DE) 1982-10-27 EP disclosed
US-4269773-A CEPHALOSPORINS SHIONOGI & CO., LTD. (JP) 1981-05-26 US disclosed
US-4249931-A 5-Oxy or thiomethyl substituted oxazolidine herbicide antidotes STAUFFER CHEMICAL COMPANY (US) 1981-02-10 US disclosed
EP-0011693-A1 N-trifluoromethane-sulfonylaminophenyl-substituted N-heterocycles, their preparation, compositions containing them and their use in regulating plant growth CIBA-GEIGY AG (CH) 1980-06-11 EP disclosed
US-4159984-A METAL AND PROTON DONOR SHIONOGI & CO., LTD. (JP) 1979-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210704-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF FKBP1B, MALT1, FKBP5 MAPK1 1050/4885SIGMAR1 3999/4885ALDH1A1 2376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.